Tiziana Life Sciences announces updated clinical, PET scan findings

Tiziana Life Sciences announced positive findings have been seen in a total of six out of eight Intermediate Size Patient Population Expanded Access, EA, patients. These patients have shown improvements in fatigue scores measured by the Modified Fatigue Impact Scale, MFIS. PET scan findings showing a reduction in microglial activation was also seen in the six patients with MFIS score improvement at the three-month evaluation period. PET scan findings for two additional EA patients are planned to be available in late January. Gabriele Cerrone, Chairman, acting CEO and founder of Tiziana Life Sciences noted “We’ve seen continued clinical and qualitative PET scan improvement over time in patients with na-SPMS where intranasal foralumab targets inflammation in the brain. It is my expectation that we will rapidly progress our ongoing Phase 2 trial of intranasal foralumab, given the encouraging results seen so far under the EA IND.”